# Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide

> **NCT05359783** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vastra Gotaland Region** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer
- Sentinel Lymph Node

## Interventions

- **DRUG:** Superparamagnetic Iron Oxide

## Key facts

- **NCT ID:** NCT05359783
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2023-02-15
- **Final completion:** 2024-04-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359783, "Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05359783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*